Using tiny internal antibodies to block LINE‑1 proteins linked to brain diseases
Development of a novel model to study the effects of LINE-1 retrotransposons in disease and normal physiology using nanobodies
['FUNDING_R21'] · MERCER UNIVERSITY MACON · NIH-11143936
Researchers are creating tiny antibody tools to block LINE‑1 proteins that may play a role in Alzheimer’s and related conditions.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | MERCER UNIVERSITY MACON (nih funded) |
| Locations | 1 site (MACON, UNITED STATES) |
| Trial ID | NIH-11143936 on ClinicalTrials.gov |
What this research studies
If you or a loved one has Alzheimer’s disease or a related condition, this project aims to make tiny internal antibodies (nanobodies) that can bind to LINE‑1 proteins inside cells and turn them off. The team will use phage display to find high‑affinity nanobodies, then test those nanobodies in lab models to see how blocking LINE‑1 proteins changes cell behavior. The goal is to produce a reliable lab model to separate harmful LINE‑1 effects from normal biology and to enable clearer follow-up studies. This is preclinical laboratory work and would be an early step toward possible future treatments rather than a direct therapy today.
Who could benefit from this research
Good fit: People with Alzheimer’s disease, Aicardi‑Goutières syndrome, or other conditions where LINE‑1 activity is suspected may be future beneficiaries or candidates for follow‑on clinical studies.
Not a fit: People seeking immediate treatment or those with conditions unrelated to LINE‑1 activity are unlikely to get direct benefit from this basic lab project.
Why it matters
Potential benefit: If successful, this work could create new tools that speed the development of targeted therapies for diseases where LINE‑1 activity contributes to damage, like some dementias and inflammatory brain disorders.
How similar studies have performed: This is a novel approach: reliable knockdown of LINE‑1 proteins using intracellular nanobodies has not been widely established before.
Where this research is happening
MACON, UNITED STATES
- MERCER UNIVERSITY MACON — MACON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: COOK, PAMELA — MERCER UNIVERSITY MACON
- Study coordinator: COOK, PAMELA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Aicardi Goutieres syndrome, Alzheimer disease dementia, Alzheimer syndrome, Alzheimer's Disease